BUZZ-Valneva jumps on 'attractive' risk/reward profile ahead of vaccine's phase 3 results

Reuters02-04
BUZZ-Valneva jumps on 'attractive' risk/reward profile ahead of vaccine's phase 3 results

** Shares in Valneva VLS.PA jump 8.6% after brokerage Oddo BHF says it sees an attractive risk/reward on the stock ahead of the phase 3 results for its Lyme disease vaccine VLA15 expected in the coming weeks

** Valneva posted positive Phase 2 data in November 2025 showing strong efficacy and safety data for VLA15, prompting brokerage to find the risk/reward attractive and remark that the partnership with Pfizer secures operational execution

** "We anticipate peak sales of 1 billion euros ($1.18 billion) in 2035, based on a launch by Pfizer in 2027 in the US and Europe," Oddo BHF says

** "In a market segment with high potential and where competition remains non-existent, VLA15 thus occupies a unique position," broker adds

** Including session's rise, the stock has gained 14% YTD

($1 = 0.8460 euros)

(Reporting by Hugo Lhomedet)

((hugo.lhomedet@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment